Selected publications
-
Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: A randomised phase 2 trial.
The Lancet.
2014
Academic Article
GET IT
Times cited: 74 -
The Study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): Design and rationale.
American Heart Journal.
2012
Academic Article
GET IT
Times cited: 20 -
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction - REVEAL: A randomized controlled trial.
JAMA - Journal of the American Medical Association.
2011
Academic Article
GET IT
Times cited: 161 -
Evaluation of a new heparin agent in percutaneous coronary intervention: Results of the Phase 2 evaluation of M118 in pErcutaNeous coronary intervention (EMINENCE) trial.
Circulation.
2010
Academic Article
GET IT
Times cited: 18 -
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
Circulation.
2008
Academic Article
GET IT
Times cited: 110 -
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Circulation.
2006
Academic Article
GET IT
Times cited: 157